Navigation Links
Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
Date:10/24/2007

Researchers share updates about sleep apnea and sleep behavior disorders

ROCHESTER, Minn., Oct. 24 /PRNewswire-USNewswire/ -- Mayo Clinic physicians offered updates about diagnosing and treating patients with a variety of sleep disorders, including obstructive sleep apnea and sleep behavior disorders, at CHEST 2007, the annual meeting of the American College of Chest Physicians in Chicago on Oct. 20-25. The following are brief summaries of select presentations.

More than 12 million people in the United States have obstructive sleep apnea, a potentially serious disorder in which breathing repeatedly stops and starts during sleep when the throat muscles relax

People with the rapid eye movement (REM) sleep disorder known as REM behavior disorder (RBD) sometimes act out their dreams by yelling or moving violently during REM sleep. A rare condition, RBD affects between 0.4 percent and 0.5 percent of the population.

Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat thousands of patients who have sleep disorders. For more information on the treatment of sleep disorders at Mayo Clinic, visit http://www.mayoclinic.org/sleep-disorders/.

Obstructive Sleep Apnea Linked with Cardiovascular Problems

Daytime fatigue, sleepiness and sleep-deprived bed partners are several symptoms commonly observed in patients with obstructive sleep apnea. More serious, however, are the cardiovascular problems associated with this sleep disorder.

Mayo Clinic pulmonologist Kannan Ramar, M.B.B.S., M.D., describes how physiological changes that occur during obstructive sleep apnea episodes affect the cardiovascular system. Sudden drops in blood-oxygen levels increase blood pressure and strain the cardiovascular system. About half of those with sleep apnea develop high blood pressure (hypertension), which raises their risk of heart failure and stroke. Obstructive sleep apnea may be associated with strokes, coronary artery disease and metabolic problems such as diabetes. Repeated multiple episodes of low blood oxygen (hypoxia or hypoxemia) can also lead to sudden death from a cardiac problem in people with underlying heart disease. Also, there is a strong association between obstructive sleep apnea and dangerous heart rhythm changes (dysrhythmias).

"Mounting data suggests that obstructive sleep apnea contributes to cardiovascular disease, independent of obesity and other cardiovascular risk factors," explains Dr. Ramar. "Considering that obstructive sleep apnea is treatable, establishing causality with other cardiovascular disorders has far-reaching implications. Long-term studies are needed to assess the impact that treatment with continuous positive airway pressure (CPAP)and other treatment modalities has upon cardiovascular outcomes."

CPAP therapy is a preferred method of treating sleep apnea. A machine delivers air pressure through a mask placed over the nose during sleep. CPAP elevates the air pressure in the upper airway passages slightly to keep these passages open, and to prevent apnea and snoring.

Consensus needed on treatment options for obstructive sleep apnea

Mayo Clinic pulmonologist Peter Gay, M.D., discusses trends in the care of people with obstructive sleep apnea. Dr. Gay notes that while experts now universally accept the need to consider this condition as a chronic disease, more research and discussion is needed to establish consensus about the best and most practical way to manage the long-term care for people with this disorder.

"Given that the use of CPAP therapy can be challenging for a large minority of patients (up to 30 percent to 40 percent), we need research to address several questions related to how we may better optimize adherence to therapy," explains Dr. Gay. "Asking 'How important is the immediate or near-immediate introduction of continuous positive airway pressure (CPAP) therapy in these patients?' and 'How early and frequently should these patients be seen in follow-up?' is important. Answering these questions will help us refine our chronic care plans and give further insight into how we may reduce several conditions such as cardiovascular disease, mood disorders, and accidents, all of which are associated with sleep apnea."

Rare Sleep Disorder Marked by Excessive and Sometimes Violent Movements

People with RBD might yell or move excessively during sleep. According to Mayo pulmonologist John Park, M.D., these episodes occur when the muscle paralysis normally present during rapid eye movement (REM) sleep is incomplete or absent, allowing the person to physically act out his or her dreams.

"This condition is usually brought to our attention when a bed partner reports being struck or physically harmed or observes the patient harming himself or herself in the midst of a dream enactment," says Dr. Park.

Dr. Park notes that while the symptoms of RBD can be alarming, the disorder can be treated. Sometimes the behavior is related to untreated sleep apnea and the condition resolves with regular sleep apnea treatment. For RBD where the cause is unknown (idiopathic RBD), treatment usually includes making the sleep environment safer, and use of medications, depending on the severity of episodes.

Seeking treatment for RBD also allows the patient to be monitored for signs of neurological disorders such as Parkinson's disease and other forms of dementia, which some patients with RBD have or develop later.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories. For more on Mayo Clinic research, go to http://www.mayo.edu.


'/>"/>
SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):